EpiAxis has appointed The Sage Group to lead the partnering program for its peptide candidates which modulate the epigenetic control of metastatic cancer.

SYDNEY, AUSTRALIA, August 12, 2019 /EINPresswire.com/ — Following a strategic review of its clinical and commercial development options, EpiAxis has appointed The Sage Group to lead the partnering program for its leading peptide candidates capable of modulating the epigenetic control of metastatic cancer.

EpiAxis Therapeutics (“EpiAxis”) seeks a global strategic partner with which it can collaborate to exploit its new family of oncology drugs. These are based on its dual- pronged, epigenetic platform to prevent and reverse metastasis.

Read full press release here.